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ABSTRACT
Background. The course of health-related quality of life
(HRQOL) during and after completion of neoadjuvant
chemoradiotherapy (nCRT) for esophageal or junctional
carcinoma is unknown.
Methods. This study was a multicenter prospective cohort
investigation. Patients with esophageal or cancer to be
treated with nCRT plus esophagectomy were eligible for
inclusion in the study. The HRQOL of the patients was
measured with European Organization for Research and
Treatment of Cancer QLQ-C30, QLQ-OG25, and QLQ-
CIPN20 questionnaires before and during nCRT, then 2, 4,
6, 8, 10, 12, 14, and 16 weeks after nCRT and before
surgery. Predefined end points were based on the hypoth-
esized impact of nCRT. The primary end points were
physical functioning, odynophagia, and sensory symptoms.
The secondary end points were global quality of life,
fatigue, weight loss, and motor symptoms. Mixed modeling
analysis was used to evaluate changes over time.
Results. Of 106 eligible patients, 96 (91%) were included
in the study. The rate of questionnaires returned ranged
from 94% to 99% until week 12, then dropped to 78% in
week 16 after nCRT. A negative impact of nCRT on all
HRQOL end points was observed during the last cycle of
nCRT (all p\ 0.001) and 2 weeks after nCRT (all
p\ 0.001). Physical functioning, odynophagia, and sen-
sory symptoms were restored to pretreatment levels
respectively 8, 4, and 6 weeks after nCRT. The secondary
end points were restored to baseline levels 4–6 weeks after
nCRT. Odynophagia, fatigue, and weight loss improved
after nCRT compared with baseline levels at respectively 6
(p\ 0.001), 16 (p = 0.001), and 12 weeks (p\ 0.001).
Conclusion. After completion of nCRT for esophageal
cancer, HRQOL decreases significantly, but all HRQOL
end points are restored to baseline levels within 8 weeks.
Odynophagia, fatigue, and weight loss improved
6–16 weeks after nCRT compared with baseline levels.
Neoadjuvant chemoradiotherapy (nCRT) followed by
surgery is a standard of care for patients with potentially
curable esophageal or esophagogastric junctional cancer.1,2
Although esophagectomy has a profound impact on both
long- and short-term patient health-related quality of life
(HRQOL), addition of nCRT to surgery does not jeopar-
dize HRQOL after surgery compared with surgery alone.3,4
However, immediately after completion of nCRT (before
surgery), patients show a profound drop in HRQOL com-
pared with baseline levels.3,5,6 This deterioration improves
after surgery, suggesting that HRQOL is restored in the
period between completion of nCRT and surgery.3,5
However, the detailed course of HRQOL during and after
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completion of nCRT is unknown. Such information might
have an impact on the timing of surgery, although this is
debated. Traditionally, surgery is scheduled 4–6 weeks
after completion of nCRT. However, findings have shown
that a longer time to surgery (up to 12 weeks) does not
endanger oncologic outcome.7 Increasing the time to sur-
gery allows patients to recover from nCRT and optimize
their physical condition before surgery. Furthermore, a
longer waiting time to surgery is suggested to increase the
pathologically complete response rate (i.e., no viable tumor
cells in the resection specimen), which might improve
prognostication.7
This study aimed primarily to assess the course of
HRQOL in the period from the start of nCRT until surgery
for patients with locally advanced esophageal or junctional
carcinoma.
METHODS
A multicenter prospective cohort study was conducted.
Patients with locally advanced esophageal or esophago-
gastric junctional cancer, as determined by endoscopic
ultrasound, computed tomography (CT) and/or positron
emission tomography (PET)-CT, who would be undergoing
nCRT according to the ChemoRadiotherapy for Oesopha-
geal cancer followed by Surgery Study (CROSS) regimen
(weekly administration of carboplatin and paclitaxel plus
41.4-Gy concurrent radiotherapy) were considered eligible
for the study.1 Patients considered insufficiently fluent in
the Dutch language or cognitively unable to understand the
questionnaire were excluded. Consecutive patients were
recruited before the start of nCRT in the Erasmus MC–
University Medical Centre, Rotterdam, and in the Elisa-
beth-Tweesteden Hospital, Tilburg. The study was
approved by the ethics committee of the Erasmus MC
(MEC-2016-250).
HRQOL Measurement
Patients were informed about the study by their own
physician. Subsequently, patients were asked to participate
via telephone by one of the investigators. Participating
patients received the self-report questionnaires by mail and
were asked by telephone to complete the questionnaire at
baseline (before nCRT), at the date of the last nCRT cycle,
and every 2 weeks thereafter until the date of surgery, with
a maximum follow-up period of 16 weeks after completion
of nCRT. All the patients completed the questionnaires
themselves and were reminded twice via telephone by one
of the investigators during each assessment.
Cancer-related general HRQOL was measured with the
European Organization for Research and Treatment of
Cancer (EORTC) QLQ-C30, a validated questionnaire for
cancer patients.8 Esophageal cancer-specific HRQOL was
assessed with the EORTC QLQ-OG25, a validated ques-
tionnaire for patients with cancer of the esophagus, the
esophago-gastric junction, and the stomach.9 Chemother-
apy-induced peripheral neuropathy (CIPN) symptoms were
assessed using the EORTC QLQ-CIPN20, a questionnaire
designed to elicit patients’ experience of symptoms related
to CIPN.10
Before the start of the study, end points were defined by
individual consensus discussion with upper gastrointestinal
(GI) surgical oncologists, medical oncologists, and nurse
practitioners. One primary end point and one or two sec-
ondary end points from each questionnaire were chosen
based on the hypothesized impact of nCRT. This led to
assignment of physical functioning (EORTC QLQ-C30),
odynophagia (EORTC QLQ-OG-25), and sensory symp-
toms (EORTC QLQ-CIPN20) as primary end points, and to
global quality of life, fatigue (both QLQ-C30), weight loss
(EORTC QLQ-OG25), and motor symptoms (EORTC
QLQ-CIPN20) as secondary end points.
Statistical Analysis
Data were analyzed on an intention-to-treat basis. Pre-
treatment clinicopathologic characteristics were collected
and described. Questionnaire scores were transformed into
a 0–100 scale according to EORTC guidelines.11 Higher
scores for functional and global scales (e.g., physical
functioning and global quality of life) indicate better
HRQOL. Higher scores on symptom scales (e.g., fatigue)
indicate worse HRQOL.
Over-time changes in the follow-up measurements were
analyzed using mixed modeling analysis, a technique that
enables analysis of all completed questionnaires by
allowing for inclusion of data from patients with different
numbers of completed measurements.12 Mean over-time
differences were described.
Cohen’s d (CD) effect sizes based on the beta estimates
from the mixed modeling analyses were used to allow for
standardized comparison between different end points and
to assess clinical relevance of the found effects. The CD
values of 0.2, 0.5, and 0.8 indicate small, medium, and
large effects, respectively.13 Effect sizes of 0.5 or larger
were defined as clinically relevant.14
On an exploratory basis, we investigated the effects of
several background variables on the trajectory of HRQOL
scores. Because the investigated sample showed variation
in timing of surgery, this could have influenced the course
of HRQOL.
Some patients (n = 29) participated in the diagnostic
preSANO trial.15,16 In that trial, the patients underwent a
clinical response evaluation (CRE) using endoscopy with
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biopsies, endoscopic ultrasound, and PET-CT 4–6 weeks
after nCRT to determine the accuracy of residual disease
detection. The patients with residual disease or non-pass-
able tumor during the clinical response evaluation after
4–6 weeks underwent immediate surgical resection,
whereas the remaining patients had surgery 10–14 weeks
after completion of nCRT.
Patients with (substantial) residual disease after nCRT
might experience worse HRQOL after nCRT, which
potentially induces a bias. Furthermore, variations in time
to surgery can be attributed to patient-related characteris-
tics such as comorbidities or general condition. More
vulnerable patients could have a longer time until surgery
intentionally. This might negatively influence HRQOL at
longer follow-up measurements, so HRQOL may improve
more strongly at the later measures if all patients could
have been included. Therefore, the study included the
presence of residual disease during clinical response eval-
uation (only for patients who participated in the preSANO
trial), comorbidities (Charlson Comorbidity Index), the
American Society of Anesthesiology (ASA) score, age,
gender, histology, and cT stage in a separate analysis to
investigate their potential effect on the course of
HRQOL.17
As a correction for multiple comparisons, a p value
lower than 0.006 was considered statistically significant (a
Bonferroni correction of 0.05/9 was applied because the
main analyses included nine comparisons with pretreat-
ment levels). All p values were two-sided. Data were
analyzed using SPSS version 24.0 (IBM, Chicago, IL,
USA).
RESULTS
Of 106 eligible patients, 96 (91%) were included from
May 2016 through June 2017 (10 patients refused partici-
pation). The rates of response to the questionnaires ranged
from 78 to 99% (Table 1). The median age of the patients
was 68 years (interquartile range [IQR], 61–71 years), and
TABLE 1 Eligibility status of the study patients
Status Baseline Last
cycle
2
Weeks
4
Weeks
6
Weeks
8
Weeks
10
Weeks
12
Weeks
14
Weeks
16
Weeks
Eligible 96 96 96 96 93 88 56 49 42 32
Total returned questionnaires (% of
eligible)
95 (99) 90 (94) 93 (97) 92 (96) 89 (96) 83 (94) 51 (91) 46 (94) 37 (88) 25 (78)
Surgery (cumulative) 0 0 0 0 3 8 39 46 53 63
Deceased 0 0 0 0 0 0 1 1 1 1
Too ill 0 4 1 1 1 1 1 1 3 4
Randomly missing/other 1 2 2 3 3 4 4 2 2 3
TABLE 2 Clinicopathologic characteristics of the study patients
Characteristic (n = 96)
n (%)
Age at inclusion (years)
Median 68
IQR 61–71
Male sex 77 (80)
Tumor type
Squamous cell carcinoma 18 (19)
Adenocarcinoma 78 (81)
Clinical T stagea
cT1 1 (1)
cT2 15 (16)
cT3 77 (80)
cT4 3 (3)
Clinical N stageb
cN0 33 (34)
cN1 38 (4)
cN2 19 (20)
cN3 6 (6)
ASA classificationc
1 15 (16)
2 65 (68)
3 14 (15)
Missing 2 (2)
IQR interquartile range, ASA American Society of Anesthesiology
aClinical tumor (cT) stage was assessed via endoscopic ultrasonog-
raphy or computed tomography (CT) and classified according to the
International Union for Cancer Control (IUCC) tumor-node-metas-
tasis (TNM) classification, 7th ed
bClinical lymph-node (N) stage was assessed via endoscopic ultra-
sonography, CT, or 18F-fluorodeoxyglucose positron-emission
tomography and classified according to IUCC TNM classification, 7th
ed
cASA classification is on a scale of 0 to 5, with lower numbers
indicating better physical status, 1 indicating a normal healthy patient,
2 indicating a patient with mild systemic disease, and 3 indicating a
patient with severe systemic disease
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77 (80%) of the patients were men. Most of the patients
had cT3 tumor (80%) and suspicious regional lymph nodes
(66%; Table 2).
Predefined Primary End Points
Physical Functioning (Fig. 1a) The over-time changes in
physical functioning levels were statistically significant
(p\ 0.001). Physical functioning had declined at the last
cycle of nCRT (- 16; p\ 0.001; CD - 0.80; 95%
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FIG. 1 Mean scores with
standard deviations for
a physical functioning,
b odynophagia, c sensory
symptoms (primary end points),
d global quality of life,
e fatigue, f weight loss, and
g motor symptoms (secondary
end points)
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confidence interval [CI], - 1.00 to - 0.59) compared with
the baseline levels. During the follow-up period, physical
functioning improved from 2 to 10 weeks after nCRT (4 vs
2 weeks: ? 6; p\ 0.001; CD 0.30; 95% CI 0.17–0.42; 6
vs 4 weeks: ? 6; p\ 0.001; CD 0.28; 95% CI 0.17–0.39;
8 vs 6 weeks: ?5; p\ 0.001; CD 0.24; 95% CI 0.15–0.32;
10 vs 8 weeks: ? 3; p = 0.003; CD 0.15; 95% CI
0.05–0.24, respectively). From this point, the
improvement was no longer statistically significant.
Baseline levels were reached at 8 weeks (p = 0.95) but
were not exceeded during the follow-up period.
Odynophagia (Fig. 1b) The over-time changes in
odynophagia levels were statistically significant
(p\ 0.001). Compared with the baseline levels, the
odynophagia levels had worsened at the last cycle of
nCRT (14; p\ 0.001; CD - 0.45; 95% CI 0.20–0.70) and
remained at that level 2 weeks after nCRT (p = 0.038).
Thereafter, the odynophagia levels improved from 2 to
4 weeks (- 21; p\ 0.001; CD - 0.69; 95% CI - 0.89 to
- 0.49), and from 4 to 6 weeks (- 11; p\ 0.001; CD
- 0.37; 95% CI - 0.50 to - 0.24). After that,
improvement was no longer statistically significant
compared with the previous measurement. At 4 weeks
after nCRT, baseline levels were reached (p = 0.68), and at
6 weeks, the odynophagia levels had improved compared
with baseline levels (6 weeks: - 15; p\ 0.001; CD
- 0.42; 95% CI - 0.64 to - 0.20; 10 weeks: - 24;
p\ 0.001; CD - 0.77; 95% CI - 0.98 to - 0.57).
Sensory Symptoms (Fig. 1c) Generally, the over-time
changes in sensory symptoms were not statistically
significant (p = 0.009). However, the specific
comparisons between occasions showed that sensory
symptoms had worsened at the last cycle of nCRT
compared with pretreatment levels, (?4: p\ 0.001; CD
0.53; 95% CI 0.28–0.80). At 6 weeks after nCRT, sensory
symptoms had returned to baseline levels (p = 0.013). No
further statistically significant improvement compared with
previous measurements was observed.
Predefined Secondary End Points
Global Quality of Life (Fig. 1d) The global quality-of-
life scores showed statistically significant changes over
time (p\ 0.001). At the last cycle of nCRT, the global
quality-of-life scores had declined (- 16: p\ 0.001; CD
- 0.77; 95% CI - 0.96 to - 0.57) and had further
worsened 2 weeks thereafter (- 6: p = 0.002; CD
- 0.29; 95% CI - 0.47 to - 0.11). From 2 to 8 weeks
after nCRT, the global quality-of-life levels improved
compared with the previous measurement (4 vs 2 weeks:
? 11; p\ 0.001; CD 0.51; 95% CI 0.33–0.69; 6 vs
4 weeks: ? 7; p\ 0.001; CD 0.34; 95% CI 0.19–0.49; 8
vs 6 weeks: ? 5; p = 0.001; CD 0.24; 95% CI 0.10–0.39,
respectively). After that, improvement was no longer
statistically significant. At 6 weeks after nCRT, baseline
levels were reached (p = 0.031). The baseline levels were
not exceeded during the follow-up period.
Fatigue (Fig. 1e) Over time, the fatigue levels changed
significantly (p\ 0.001). Compared with baseline, the
fatigue levels had increased at the last cycle of nCRT
(? 34: p\ 0.001; CD 1.21; 95% CI 1.04–1.39) and
remained stable until 2 weeks after nCRT (p = 0.32).
After that, improvement was observed until 6 weeks
compared with the previous measurements (4 vs 2 weeks:
- 15; p\ 0.001; CD - 0.57; 95% CI - 0.73 to - 0.41; 6
vs 4 weeks: - 13; p\ 0.001; CD - 0.46; 95% CI - 0.60
to - 0.32). Baseline levels were reached at 6 weeks
(p = 0.007). Thereafter, no statistically significant
improvement compared with the previous measurement
was observed. Compared with baseline levels,
improvement was observed 16 weeks after nCRT (- 8;
p = 0.001; CD - 0.28; 95% CI - 0.44 to - 0.11).
Weight Loss (Fig. 1f) The weight loss scores changed
significantly over time (p\ 0.001). At the last cycle of
nCRT, weight loss had worsened compared with baseline
levels (? 10: p = 0.002; CD 0.36; 95% CI 0.13–0.58) and
did not improve 2 and 4 weeks after nCRT compared with
the previous measurement (p = 0.263 and 0.038,
respectively). The scores then returned to baseline levels
4 weeks after nCRT (p = 0.031) and improved further (6
vs 4 weeks: 9; p\ 0.001; CD - 0.31; 95% CI - 0.47 to
- 0.16; 8 vs 6 weeks: - 7; p\ 0.001; CD - 0.24; 95%
CI - 0.37 to - 0.12). At 12 weeks after nCRT, the weight
loss scores had improved compared with baseline levels
(- 15; p\ 0.001; CD - 0.52; 95% CI - 0.79 to - 0.26).
Motor Symptoms (Fig. 1g) The over-time change in
motor symptoms was statistically significant (p\ 0.001).
Motor symptoms had worsened at the last cycle of nCRT
(? 4; p\ 0.001). At 4 weeks after nCRT, the motor
symptoms had returned to baseline levels (p = 0.028). No
further improvements in motor symptoms compared with
previous measurements was observed.
Other End Points The mean scores of HRQOL domains,
except for the predefined end points, are presented in
Table 3.
Influence of Residual Disease, Comorbidities, and General
Condition Inclusion of residual disease present during
the clinical response evaluation, comorbidities (Charlson
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Comorbidity Index), ASA score, age, gender, histology,
and cT stage as control variables did not have an impact on
the reported overall trends in HRQOL trajectories (data not
shown). However, the patients who had residual disease
during CRE exhibited worse odynaphagia levels. The
patients with higher Charlson Comorbidity Index (CCI)
experienced more fatigue, and the patients with a higher cT
stage had more weight loss (Table S1). Furthermore, the
patients who had residual disease during CRE or a higher
ASA score had increased weight loss over time (Table S2;
Fig. S1).
DISCUSSION
This prospective cohort study showed a profound neg-
ative, short-term impact of nCRT on all HRQOL end points
for patients who had esophageal or junctional cancer
treated with a multimodality regimen based on carbo-
platin/paclitaxel combined with 41.4 Gy of concurrent
TABLE 3 Mean scores for all domains in the three European Organization for Research and Treatment of Cancer (EORTC) questionnaires that
were not predefined end points
Status Baseline Last
cycle
2
Weeks
4
Weeks
6
Weeks
8
Weeks
10 Weeks 12
Weeks
14
Weeks
16
Weeks
QLQ-C30
Functional scales
Role 82 ± 23 56 ± 32 50 ± 32 26 ± 30 71 ± 27 79 ± 23 81 ± 22 81 ± 25 82 ± 25 85 ± 25
Emotional 75 ± 20 74 ± 24 72 ± 23 78 ± 19 80 ± 20 81 ± 17 81 ± 19 83 ± 16 82 ± 17 82 ± 19
Cognitive 91 ± 16 81 ± 25 82 ± 20 86 ± 19 91 ± 16 92 ± 16 91 ± 17 93 ± 14 93 ± 13 95 ± 12
Social 88 ± 18 70 ± 30 69 ± 27 78 ± 23 86 ± 20 88 ± 18 89 ± 18 89 ± 18 90 ± 19 91 ± 18
Symptom scores
Nausea and vomiting 12 ± 23 28 ± 30 32 ± 32 13 ± 20 10 ± 19 5 ± 15 3 ± 8 5 ± 11 5 ± 11 1 ± 3
Pain 14 ± 19 32 ± 28 38 ± 31 22 ± 26 14 ± 20 11 ± 20 12 ± 22 11 ± 21 12 ± 24 9 ± 19
Dyspnea 8 ± 16 20 ± 26 22 ± 26 20 ± 26 12 ± 21 11 ± 21 11 ± 21 13 ± 19 11 ± 19 8 ± 15
Insomnia 27 ± 30 35 ± 33 33 ± 34 24 ± 31 20 ± 25 16 ± 24 18 ± 24 17 ± 26 14 ± 20 12 ± 25
Loss of appetite 21 ± 28 46 ± 35 52 ± 35 33 ± 34 18 ± 26 12 ± 24 12 ± 22 12 ± 24 11 ± 21 7 ± 17
Constipation 9 ± 21 25 ± 33 25 ± 32 13 ± 24 7 ± 16 5 ± 14 7 ± 15 4 ± 13 4 ± 10 7 ± 17
Diarrhea 6 ± 17 16 ± 26 15 ± 26 5 ± 16 4 ± 12 5 ± 13 7 ± 13 3 ± 9 4 ± 13 5 ± 12
Financial worries 3 ± 12 8 ± 22 6 ± 18 5 ± 14 5 ± 17 5 ± 16 4 ± 16 4 ± 13 4 ± 10 4 ± 11
QLQ-OG25
Symptom scores
Dysphagia 27 ± 25 41 ± 28 56 ± 30 25 ± 25 16 ± 19 13 ± 21 10 ± 17 6 ± 12 6 ± 15 4 ± 7
Eating 42 ± 28 57 ± 28 62 ± 28 40 ± 31 27 ± 28 20 ± 27 16 ± 23 13 ± 20 10 ± 17 9 ± 15
Reflux 9 ± 18 14 ± 23 16 ± 26 8 ± 21 5 ± 14 3 ± 10 3 ± 12 3 ± 11 1 ± 6 1 ± 7
Pain and discomfort 15 ± 23 29 ± 28 30 ± 32 22 ± 28 14 ± 23 13 ± 22 10 ± 1912 7 ± 17 7 ± 17 10 ± 20
Anxiety 52 ± 25 46 ± 26 47 ± 27 43 ± 25 41 ± 27 43 ± 26 42 ± 26 41 ± 22 39 ± 26 36 ± 27
Eating with others 27 ± 33 34 ± 35 36 ± 26 21 ± 30 11 ± 24 7 ± 17 5 ± 12 5 ± 14 4 ± 10 1 ± 7
Dry mouth 13 ± 23 26 ± 28 29 ± 30 17 ± 24 13 ± 20 9 ± 20 12 ± 21 13 ± 27 9 ± 22 7 ± 14
Trouble with taste 18 ± 32 44 ± 37 46 ± 35 32 ± 32 21 ± 27 12 ± 24 10 ± 20 8 ± 20 5 ± 12 7 ± 17
Trouble swallowing
saliva
13 ± 27 24 ± 32 24 ± 30 14 ± 26 7 ± 18 5 ± 15 3 ± 11 3 ± 12 2 ± 8 3 ± 9
Choking when
swallowing
10 ± 22 9 ± 17 9 ± 18 5 ± 14 3 ± 10 4 ± 13 2 ± 9 4 ± 13 5 ± 14 3 ± 9
Trouble with coughing 26 ± 26 32 ± 28 34 ± 28 28 ± 27 21 ± 23 23 ± 24 19 ± 24 19 ± 25 17 ± 22 16 ± 17
Trouble talking 6 ± 18 10 ± 19 13 ± 24 8 ± 18 3 ± 10 3 ± 11 5 ± 13 4 ± 13 4 ± 10 4 ± 11
Hair loss 10 ± 25 22 ± 29 19 ± 26 21 ± 29 19 ± 31 16 ± 26 14 ± 28 14 ± 31 17 ± 36 5 ± 13
QLQ-CIPN20
Autonomic scale 11 ± 15 21 ± 19 22 ± 19 18 ± 18 14 ± 16 14 ± 15 14 ± 15 14 ± 16 14 ± 18 14 ± 18
Scores are presented as means ± standard deviations
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radiotherapy. Subsequently, all primary and secondary
HRQOL end points were restored to baseline levels
4–10 weeks after completion of nCRT. The odynophagia,
fatigue, and weight loss scores even improved after nCRT
compared with baseline levels at 6, 16, and 12 weeks,
respectively.
This is the first study to investigate the detailed short-
term course of HRQOL after nCRT for esophageal or
junctional cancer. A previous study showed a negative
impact of nCRT on HRQOL 12 weeks after the start of
neoadjuvant treatment, which was restored to baseline
levels 3 weeks before surgery.6 However, this earlier study
used a small sample (n = 34), only two measurements after
nCRT with respect to the start of nCRT rather than the end
of nCRT, and the date of surgery, hampering precise
assessment of the HRQOL trajectory after nCRT. A study
using the Functional Assessment of Cancer Therapy-Eso-
phageal (FACT-E) demonstrated findings similar to those
in the current study in terms of return to baseline before
surgery, but included only patients who had neoadjuvant
chemotherapy.18
The HRQOL analysis in the CROSS trial also showed a
profound deterioration 1 week after completion of nCRT
compared with baseline scores for all primary and sec-
ondary HRQOL end points (physical functioning, global
quality of life, fatigue, eating, and emotional functioning).
However, this study lacked extra measurements between
the end of nCRT and the date of surgery.3
The results of the current study underscore the value of
sufficient recuperation time between completion of nCRT
and esophagectomy to enable patients to undergo surgery
in optimal physical condition, potentially improving sur-
gical outcome. Moreover, delayed surgery tends to increase
the pathologically complete response rate, potentially
improving prognosis.7,19 We recommend that timing of
surgery be guided by the patient’s condition. It is advo-
cated that surgery be postponed to as long as 12 weeks
after completion of nCRT, and even longer than that when
patients experience persisting adverse events or are in bad
general condition, especially in the absence of residual
disease.
Previous studies have shown lasting deterioration of
HRQOL after multimodality treatment for patients with
esophageal cancer.4,20–22 Given the current results, these
negative findings likely are attributable to esophagectomy
and not to chemoradiotherapy per se. Definitive chemora-
diotherapy without esophagectomy circumvents the
adverse effects of surgery. However, the long-term onco-
logic outcome is suggested to be inferior to (nCRT plus)
surgery.23
An active surveillance strategy after completion of
nCRT is a topic of investigation in the ESOSTRATE and
Surgery As Needed for Oesophageal cancer (SANO)
trials.15,24 With this novel treatment strategy, patients
undergo frequent clinical examinations after completion of
nCRT, and esophagectomy is offered only to patients with
a histologically proven or highly suspected locoregional
regrowth without signs of distant dissemination. This
active surveillance strategy might reduce the number of
patients who need esophagectomy by 30–40%, reducing
the impact of surgery on HRQOL. The results of the cur-
rent study can be used to inform patients for whom a future
active surveillance strategy is considered because the
stable HRQOL levels during the last measurements likely
reflect the HRQOL levels during active surveillance.
The limitations of the current study included the dif-
ferences in timing of surgery between patients, which
introduced different follow-up periods between patients.
Nevertheless, inclusion of the confounders, namely, the
presence of residual disease during clinical response eval-
uation (only patients in the preSANO trial), comorbidities
(Charlson Comorbidity Index), and ASA score, did not
influence the overall trends in HRQOL trajectories.
Another limitation was the potential effect of response
shift or reconceptualization of symptoms during treatment
(i.e., what was bad before is the new normal). Unfortu-
nately, this is inevitable in HRQOL studies.
In conclusion, HRQOL decreased substantially after
completion of nCRT for esophageal cancer, but was
restored to baseline levels for all end points within
10 weeks. Odynophagia, fatigue, and weight loss had
improved within 16 weeks after nCRT compared with
baseline levels. These results suggest a benefit of delaying
surgery, especially for vulnerable patients, and can be used
to inform patients for whom a future active surveillance
strategy is considered.
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